Advertisement
UK markets closed
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • CRUDE OIL

    82.97
    +1.62 (+1.99%)
     
  • GOLD FUTURES

    2,240.90
    +28.20 (+1.27%)
     
  • DOW

    39,782.93
    +22.85 (+0.06%)
     
  • Bitcoin GBP

    56,034.86
    +1,341.42 (+2.45%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    16,381.47
    -18.05 (-0.11%)
     
  • UK FTSE All Share

    4,338.05
    +12.12 (+0.28%)
     

Taking Stock of Gilead Sciences’ Key Developments

Taking Stock of Gilead Sciences’ Key Developments

During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.